Phaseline

Targets › KLB

KLB (Beta-klotho): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine.

Contributes to the transcriptional repression of cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis. Probably inactive as a glycosidase. (UniProt, Q86Z14)

Open in Phaseline: the race on KLB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Biohaven TherapeuticsTaldefgrobep Alfa
FGF21 receptor agonist (FGF21 analog)
FGFR1, FGFR4, KLBPhase 2Obesity–

Conditions

Obesity (1)

Modalities

small molecule (1)

Companies

Biohaven Therapeutics (1)

Related targets

FGFR1 (1) FGFR4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.